Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
Multiple Myeloma
Type
Interventional
Phase
Phase 1Phase 2
Design
Allocation: N/AIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

The purpose of the escalation part of the trial is to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D), as well as to establish the safety profile of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

The purpose of the escalation part of the trial is to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D), as well as to establish the safety profile of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Tracking Information

NCT #
NCT04824794
Collaborators
Not Provided
Investigators
Not Provided